PubMed Health⌕ Search

Biomedical subjects

J S Gillespie

Publications and source records attributed to J S Gillespie.

At least 19 recordsLinked to original sources

Identification of the human cytochromes p450 responsible for in vitro formation of R- and S-norfluoxetine.

The formation of R- and S-norfluoxetine was analyzed in vitro in human liver microsomes. Low apparent K(m) values for R-norfluoxetine formation of < or =8 microM and S-norfluoxetine of <0.2 microM were determined. R-Norfluoxetine formation rates in a characterized microsomal bank correlated with the catalytic activities for cytochrome P450 (CYP) 2D6, CYP2C9, and CYP2C8. Expressed CYP2C9, CYP2C19, and CYP2D6 formed R-norfluoxetine following incubation with 1 microM R-fluoxetine and exhibited apparent K(m) values of 9.7, 8.5, and 1.8 microM, respectively. Multivariate correlation analysis identified CYP2C9 and CYP2D6 as significant regressors with R-norfluoxetine formation. Antibodies to the CYP2C subfamily and CYP2D6 each exhibited moderate inhibition of R-norfluoxetine formation. Therefore, CYP2D6 and CYP2C9 contribute to this biotransformation. At pharmacological concentrations of S-fluoxetine, S-norfluoxetine formation rates in the bank of microsomes were found to correlate only with CYP2D6 catalytic activity and only expressed CYP2D6 was found to be capable of forming S-norfluoxetine. Thus, it would appear that both CYP2D6 and CYP2C9 contribute to the formation of R-norfluoxetine, whereas only CYP2D6 is responsible for the conversion to S-norfluoxetine. Since the enantiomers of fluoxetine and norfluoxetine are inhibitors of CYP2D6, upon chronic dosing, the CYP2D6-mediated metabolism of the fluoxetine enantiomers would likely be inhibited, resulting in R-norfluoxetine formation being mediated by CYP2C9 and S-norfluoxetine formation being mediated by multiple high K(m) enzymes.

Antibodies, Monoclonal↗

Double contrast barium enema and colorectal carcinoma: sensitivity and potential role in screening.

To establish the sensitivity of double contrast barium enema (DCBE) for detection of colorectal carcinoma in a tertiary referral centre and consider its possible role as a suitable imaging method in screening for this disease. A total of 160 patients with a histopathologically proven diagnosis of colorectal carcinoma over a two year period were reviewed. Subsequently 112 of the 160 patients were identified as having undergone DCBE, the results of which were analysed to determine its sensitivity for detecting colorectal carcinoma. Colorectal carcinoma was missed in 4 of the 112 barium enemas performed. This corresponds to a sensitivity of 96.5% with a false negative rate of 3.5%. The Dukes Classification in these 4 cases showed that Dukes stage B, C and D were missed, with tumours located in the right and the sigmoid colon. The mean delay to operation in these four cases was 6 weeks. Our study correlates with previous studies showing a false negative rate for DCBE of 3.5%. Colonoscopy also fails to detect small numbers of tumours with false negative rates reported as high as 10%. We suggest that double contrast barium enema should be effective as a screening method in any future colorectal cancer screening program.

Aged↗

Bilateral traumatic caroticocavernous fistulae: total resolution following unilateral occlusion.

Balloon occlusion is the accepted treatment for direct posttraumatic caroticocavernous fistula. We present a case of bilateral traumatic fistulae associated with a pseudoaneurysm. Resolution of both fistulae occurred following treatment of one of them by balloon occlusion of the internal carotid artery. This case highlights the importance of considering a more conservative approach to bilateral fistulae or those associated with a pseudoaneurysm. We review other treatment options.

Adult↗

Bilateral astrocytoma involving the limbic system precipitating disabling amnesia and seizures.

Astrocytomas involving the limbic system are usually unilateral in nature. We report a very unusual case where a low-grade astrocytoma originating in the left temporal lobe spread to the right hippocampus through the hippocampal commissure to cause disabling amnesia and seizures. Some improvement in the memory deficit was facilitated by identification of complex partial status epilepticus. EEG should be performed in all patients with lesions of the limbic system and neuropsychological problems if ongoing seizure activity is not to be missed.

Adult↗

Three- and four-dimensional-quantitative structure activity relationship (3D/4D-QSAR) analyses of CYP2C9 inhibitors.

The interaction of competitive type inhibitors with the active site of cytochrome P450 (CYP) 2C9 has been predicted using three- and four-dimensional quantitative structure activity relationship (3D-/4D-QSAR) models constructed using previously unreported and literature-derived data. 3D-QSAR pharmacophore models of the common structural features of CYP2C9 inhibitors were built using the program Catalyst and compared with 3D- and 4D-QSAR partial least-squares models, which use molecular surface-weighted holistic invariant molecular descriptors of the size and shape of inhibitors. The Catalyst models generated from multiple conformers of competitive inhibitors of CYP2C9 activities contained at least one hydrophobic and two hydrogen bond acceptor/donor regions. Catalyst model 1 was constructed with Ki(apparent) values for inhibitors of tolbutamide and diclofenac 4'-hydroxylation (n = 9). Catalyst model 2 was generated from literature Ki(apparent) values for (S)-warfarin 7-hydroxylation (n = 29), and Catalyst model 3 from literature IC50 values for tolbutamide 4-hydroxylation (n = 13). These three models illustrated correlation values of observed and predicted inhibition for CYP2C9 of r = 0.91, 0.89, and 0.71, respectively. Catalyst pharmacophores generated with Ki(apparent) values were validated by predicting the Ki(apparent) value of a test set of CYP2C9 inhibitors also derived from the literature (n = 14). Twelve of fourteen of these Ki(apparent) values were predicted to be within 1 log residual of the observed value using Catalyst model 1, whereas Catalyst model 2 predicted 10 of 14 Ki(apparent) values. The corresponding partial least-squares molecular surface-weighted holistic invariant molecular 3D- and 4D-QSAR models for all CYP2C9 data sets yielded predictable models as assessed using cross-validation. These 3D- and 4D-QSAR models of CYP inhibition will aid in future prediction of drug-drug interactions.

Anti-Inflammatory Agents, Non-Steroidal↗

Three- and four-dimensional quantitative structure activity relationship analyses of cytochrome P-450 3A4 inhibitors.

The program Catalyst was used to build three-dimensional quantitative structure activity relationship (3D-QSAR) pharmacophore models of the structural features common to competitive-type inhibitors of cytochrome P-450 (CYP) 3A4. These were compared with 3D- and four-dimensional (4D)-QSAR partial least-squares (PLS) models built using molecular surface-weighted holistic invariant molecular (MS-WHIM) descriptors for size and shape of the inhibitor. The Catalyst pharmacophore model generated from multiple conformers of competitive inhibitors of CYP3A4-mediated midazolam 1'-hydroxylation (n = 14) yielded a high correlation of observed and predicted Ki values of r = 0.91. Similarly, PLS MS-WHIM was used to produce 3D- and 4D-QSARs for this data set and produced models that were statistically predictable after cross-validation. Two additional Catalyst pharmacophores were constructed from literature Ki values (n = 32) derived from the inhibition of CYP3A-mediated cyclosporin A metabolism and IC50 data (n = 22) from the inhibition of CYP3A4-mediated quinine 3-hydroxylation. These Catalyst pharmacophores illustrated correlations of observed and predicted inhibition for CYP3A4 of r = 0.77 and 0.92, respectively. The corresponding 4D-QSARs generated by PLS MS-WHIM for these data sets were of comparable quality as judged by cross-validation. Both Ki pharmacophores generated with Catalyst were also validated by predicting the Ki(apparent) values of a test set of eight CYP3A4 inhibitors not included in either model. In seven of eight cases, the residuals of the predicted Ki(apparent) values were within 1 log unit of the observed values. The 3D- and 4D-QSAR models produced in this study suggest the utility of future in silico prediction of CYP3A4-mediated drug-drug interactions.

Catalysis↗

Selectivity of the multidrug resistance modulator, LY335979, for P-glycoprotein and effect on cytochrome P-450 activities.

Overexpression of ATP-dependent drug efflux pumps, P-glycoprotein (Pgp) or multidrug resistance-associated protein (MRP), confers multidrug resistance to tumor cells. Modulators of multidrug resistance block the action of these pumps, thereby sensitizing cells to oncolytics. A potent Pgp modulator is LY335979, which fully sensitizes Pgp-expressing cells at 0.1 microM in cytotoxicity assays and for which Pgp has an affinity of 59 nM. The present study examines its effect on MRP1-mediated drug resistance and cytochrome P-450 (CYP) activity and its ability to serve as a Pgp substrate. Drug resistance was examined with HL60/ADR and MRP1-transfected HeLa-T5 cells. Drug cytotoxicity was unaffected by 1 microM LY335979; leukotriene C4 uptake into HeLa-T5 membrane vesicles was unaffected. Because the substrate specificity of Pgp and CYP3A overlap, the effect of LY335979 on the 1'-hydroxylation of midazolam by CYP3A in human liver microsomes was examined. The apparent K(i) was 3.8 microM, approximately 60-fold higher than the affinity of Pgp for LY335979. The modulator's effect on Pgp was evaluated with Pgp-overexpressing CEM/vinblastine (VLB)(100) and parental CCRF-CEM cells. Both cell lines accumulated [(3)H]LY335979 equally well and did not efflux [(3)H]LY335979 during a 3-h incubation, indicating that it is not a substrate of Pgp. Equilibrium-binding studies with CEM/VLB(100) plasma membranes and [(3)H]LY335979 showed that Pgp had a K(d) of 73 nM, which is in good agreement with the previously determined K(i) value. Thus, LY335979 is an extremely potent Pgp, and not MRP1 or MRP2, modulator and has a significantly lower affinity for CYP3A than for Pgp.

ATP Binding Cassette Transporter, Subfamily B, Mem↗

Three and four dimensional-quantitative structure activity relationship (3D/4D-QSAR) analyses of CYP2D6 inhibitors.

Three- and four-dimensional quantitative structure activity relationship (3D/4D-QSAR) pharmacophore models of competitive inhibitors of CYP2D6 were constructed using data from our laboratory or the literature. The 3D-QSAR pharmacophore models of the common structural features of CYP2D6 inhibitors were built using the program Catalyst (Molecular Simulations, San Diego, CA, USA). These 3D-QSAR models were compared with 3D and 4D-QSAR partial least squares (PLS) models which were constructed using molecular surface-weighted holistic invariant molecular (MS-WHIM) descriptors of size and shape of inhibitors. The first Catalyst model was generated from multiple conformers of competitive inhibitors (n = 20) of CYP2D6 mediated bufurolol 1'-hydroxylation. This model demonstrated a correlation of observed and predicted Ki (apparent) values of r = 0.75. A second Catalyst model was constructed from literature derived Ki (apparent) values (n = 31) for the inhibition of CYP2D6. This model provided a correlation of observed and predicted inhibition for CYP2D6 of r = 0.91. Both Catalyst Ki pharmacophores were then validated by predicting the Ki (apparent) of a test set of known CYP2D6 inhibitors (n = 15). Ten out of 15 of these Ki (apparent) values were predicted to be within one log residual of the observed value using our CYP2D6 inhibitor model, while the literature model predicted nine out of 15 values. Similarly, 3D- and 4D-QSARs derived from PLS MS-WHIM for our dataset yielded predictable models as assessed using cross-validation. The corresponding cross-validated PLS MS-WHIM model for the literature dataset yielded a comparable 3D-QSAR and improved 4D-QSAR value. Such computational models will aid in future prediction of drug-drug interactions.

Cytochrome P-450 CYP2D6 Inhibitors↗

Three-dimensional quantitative structure activity relationship analyses of substrates for CYP2B6.

To begin to build an understanding of the interactions of CYP2B6 with substrates, two different 3-dimensional quantitative structure activity relationship (3D-QSAR) models were constructed using 16 substrates of B-lymphoblastoid expressed CYP2B6. A pharmacophore model was built using the program Catalyst, which was compared with a partial least-squares (PLS) model using molecular surface-weighted holistic invariant molecular (MS-WHIM) descriptors. The Catalyst model yielded a 3-dimensional model of the common structural features of CYP2B6 substrates, whereas PLS MS-WHIM generated a model based on statistical analyses of molecular descriptors for size and shape of the substrate. The pharmacophore model obtained with Catalyst consisted of three hydrophobes and one hydrogen bond acceptor region. The cross-validated PLS MS-WHIM model gave a good q2 value of 0.607. Size, positive electrostatic potential, hydrogen bonding acceptor capacity, and hydrophobicity were found to be the most relevant descriptors for the model. These models were then used to predict the Km (apparent) values of a test set of structurally diverse substrates for CYP2B6 not included in the model building, specifically lidocaine, amitriptyline, bupropion, arteether, and verapamil. Overall, both 3D-QSAR methods yielded satisfactory Km (apparent) value predictions for the majority of the molecules in the test set. However, PLS MS-WHIM was unable to reliably predict the Km (apparent) value for verapamil, whereas Catalyst did not predict the Km (apparent) value for lidocaine. In both of these cases the residual of the Km (apparent) value was greater than one log unit. The strengths and limitations of both of these 3D-QSAR approaches are discussed.

Aryl Hydrocarbon Hydroxylases↗

Further characterization of the expression in liver and catalytic activity of CYP2B6.

Previous studies in this laboratory have determined the lack of specificity of several antibody and substrate probes of CYP2B6. The goals of the current study were to examine the expression of CYP2B6 in a bank of human liver microsome (HLM) samples using a new specific monoclonal antibody (MAb 49-10-20) and to further characterize the substrate specificity of CYP2B6. A 100-fold variability in expression of immunodetectable CYP2B6 was demonstrated in a bank of 19 HLM samples (0.7 pmol/mg protein to 71. 1 pmol/mg protein) using MAb 49-10-20. CYP2B6 levels were found to significantly (P < .0001) correlate with S-mephenytoin N-demethylation to nirvanol (r2 = 0.89), 7-hydroxy-4-trifluoromethylcoumarin formation (r2 = 0.81) and several markers of CYP3A levels and activity. The relationships between nirvanol formation and CYP3A levels or activity were found to depend on two HLM samples. Km (apparent) values were generated for benzyloxyresorufin O-deethylation (1.3 microM), benzphetamine N-demethylation (93.4 microM), 3-cyano 7-ethoxycoumarin O-deethylation (71.3 microM), midazolam 1'-hydroxylation (46.1 microM) and 4-chloromethyl-7-ethoxycoumarin O-deethylation (33.7 microM) using expressed CYP2B6. Testosterone 16beta-hydroxylation by expressed CYP2B6 resulted in atypical kinetics characteristic of substrate activation. The data best fit the Hill equation with a Km (apparent) of 50.5 microM and an n of 1.3 (n = number of sites bound by activator). In conclusion, the highly specific MAb 49-10-20 was used to provide further confirmation that S-mephenytoin N-demethylation to nirvanol is a CYP2B6 selective probe. Finally, some, but not all substrates of CYP2B6 demonstrate autoactivation.

Antibodies, Monoclonal↗

Alterations of the catalytic activities of drug-metabolizing enzymes in cultures of human liver slices.

Precision-cut human liver slices are an important tool for defining the metabolism and hepatotoxicity of drug candidates early in development. Because of the frequent use of this in vitro tool, a knowledge of the catalytic activities of the drug-metabolizing enzymes during human liver slice culture is necessary. Therefore, marker catalytic activities for various cytochrome P450 (P450 or CYP) forms, as well as phase II activities (glucuronidation and sulfation of 7-hydroxycoumarin), were measured in slices from three different human livers during 96 hr in culture. Standard viability measures were found to be stable from 8 to 24 hr and then declined to 96 hr. Catalytic activities measured for the P450s were ethoxyresorufin O-deethylase (CYP1A2), coumarin 7-hydroxylase (CYP2A6), (S)-mephenytoin N-demethylase (CYP2B6), diclofenac 4'-hydroxylase (CYP2C9), (S)-mephenytoin 4'-hydroxylase (CYP2C19), bufuralol 1'-hydroxylase (CYP2D6), chlorzoxazone 6-hydroxylase (CYP2E1), and midazolam 1'-hydroxylase (CYP3A). The P450 activities decreased by approximately 20% by 4 hr and by at least 65% by 24 hr and were not measurable by 96 hr. In contrast to the phase I activities, 7-hydroxycoumarin glucuronosyltransferase activity was increased at the 8-hr time point by approximately 100% and then decreased to approximately initial values by 96 hr. The 7-hydroxycoumarin sulfotransferase activity of the slices decreased significantly more slowly than did the P450 activities. In conclusion, using conventional methods of liver slice preparation and culture, most of the metabolic capabilities of human liver slices are rapidly lost with time. Therefore, the development of culture methods for human liver slices that can improve the preservation of the drug-metabolizing capabilities may be required.

Catalysis↗

Non-adrenergic, non-cholinergic relaxation of the bovine retractor penis muscle: role of S-nitrosothiols.

1. This study examined the possibility that an S-nitrosothiol, rather than nitric oxide, functions as the non-adrenergic, non-cholinergic (NANC) inhibitory neurotransmitter in the bovine retractor penis (BRP) muscle. 2. Treatment of BRP muscle with either of two sulphydryl inactivating agents, diamide (1 mM) and N-ethylmaleimide (0.3 mM), inhibited NANC relaxation and this was prevented by pretreating tissues with L-cysteine (3 mM), L-glutathione (3 mM) or dithiothreitol (3 mM). Inhibition was not specific, however, since the inactivating agents also inhibited the relaxant actions of authentic nitric oxide (0.3 microM), glyceryl trinitrate (0.001-1 microM) and isoprenaline (0.01-1 microM). 3. Reacting nitric oxide with L-cysteine in nominally oxygen-free solution at pH 3, followed by purging to remove free nitric oxide and neutralisation, produced greater and more prolonged relaxant activity when assayed on rabbit aortic rings than could be attributed to nitric oxide alone. H.p.l.c. analysis of the mixture identified a new peak distinct from either L-cysteine or nitric oxide which was responsible for the relaxant activity. The spectral absorption of this new compound had two bands with peaks at 218 and 335 nm. 4. Using a series of structural analogues of L-cysteine (all at 15 mM) it was found that removal of the carboxyl group (L-cysteamine), replacement of the carboxyl with an ester function (L-cysteine methyl ester) or substitution at the amino group (N-acetyl-L-cysteine) had no effect on the ability to generate relaxant activity upon reaction with nitric oxide (0.1 mM). In contrast, substitution at the sulphydryl group (S-methyl-L-cysteine, L-cysteinesulfinic acid and L-cysteic acid), or formation of disulphides(L-cystine and L-cystamine) led to a complete loss of ability to generate relaxant activity. L-Glutathione was also able to react with nitric oxide to produce relaxant activity, and this too was blocked upon substitution of the free sulphydryl group (S-methyl-L-glutathione). A free sulphydryl group was therefore required to generate relaxant activity following reaction with nitric oxide.5. Reacting L-cysteine (10 mM) with nitric oxide (~ 3 mM) under more stringent oxygen-free conditions followed by purging to remove free nitric oxide resulted in the generation of low relaxant activity and small absorption peaks at 218 and 335 nm and these were unaffected upon exposure to the air. In contrast, admitting air to the reaction chamber before purging enhanced both relaxant activity and the absorption peaks at 218 and 335 nm by some 40 fold and the solution turned pink due to the appearance of another absorption peak at 543 nm. This enhanced relaxant activity was not due to nitrogen dioxide being the reactive species, since at 0.1 mM this gas failed to react with L-cysteine to generate relaxant activity, and at 1 mM generated less activity than the equivalent concentration of nitricoxide.6. The relaxant activity generated by reacting nitric oxide with L-cysteine or L-glutathione was abolished following treatment with haemoglobin (3 MicroM), methylene blue (10 MicroM) or Nmethylhydroxylamine(100 MicroM), but was unaffected by N0-nitro-L-arginine (30 MicroM). Furthermore, two agents that generate superoxide anion, pyrogallol (0.1 mM) and hydroquinone (0.1 mM), also inhibited this relaxant activity as well as that induced by authentic nitric oxide (0.3 MicroM) but as previously reported, had no effect on relaxation induced by NANC nerve stimulation. Superoxide dismutase(100 u ml1) reversed the actions of pyrogallol and hydroquinone but had no effect on NANC relaxation.7. In conclusion, the reaction of nitric oxide with L-cysteine or L-glutathione generates relaxant activity which exceeds that of nitric oxide alone and probably results from formation of S-nitrosocysteine and S-nitrosoglutathione, respectively. The effects of pyrogallol and hydroquinone suggest that the NANCneurotransmitter is a superoxide anion-resistant, nitric oxide-releasing molecule and that neither S-nitrocysteine nor S-nitrosoglutathione is a suitable candidate for this.

Animals↗

Increased transcription of interleukin-6 in the brains of mice with chronic enterovirus infection.

An animal model of chronic enteroviral infection was established by using PCR to detect viral genomes in animal tissues and to compare levels of transcription of a variety of cytokines in the brain. Chronic coxsackie-virus B1 infection was found in both brain and skeletal muscle of mice infected as neonates. The viral infection cleared by 240 days post-infection. Elevated levels of tumour necrosis factor alpha and interleukin-6 (IL-6) would appear to be linked to acute and chronic infection respectively. Levels of IL-6 return to normal upon clearance of the virus.

Animals↗

Actions and interactions of NG-substituted analogues of L-arginine on NANC neurotransmission in the bovine retractor penis and rat anococcygeus muscles.

1. The effects and interactions of a series of NG-substituted analogues of L-arginine known to inhibit nitric oxide synthase were examined on non-adrenergic, non-cholinergic (NANC) neurotransmission in the bovine retractor penis (BRP) and rat anococcygeus muscles. 2. Treatment of BRP muscle strips with either NG-nitro L-arginine (L-NOARG: 0.1-10 microM) or NG-nitro L-arginine methyl ester (L-NAME; 0.1-100 microM) produced a concentration-dependent blockade of NANC relaxation: blockade was complete at the highest concentration of each. 3. Pretreatment with L-arginine (1-10 mM) had no effect on NANC relaxation by itself, but inhibited, in a concentration-dependent manner, the subsequent ability of both L-NOARG (0.1-300 microM) and L-NAME (0.1-1 mM) to produce blockade. L-Arginine (1-10 mM) reversed established submaximal blockade of NANC relaxation induced by L-NOARG (1 microM) or L-NAME (1 microM), but had little effect on maximal blockade induced by these agents. 4. In contrast to L-NOARG and L-NAME, NG-monomethyl L-arginine (L-NMMA; 1 microM-1 mM) had no effect by itself on NANC relaxation of the BRP. L-NMMA (0.1-1 mM) did, however, like L-arginine, inhibit, in a concentration-dependent manner, the subsequent ability of both L-NOARG (0.1-1 mM) and L-NAME (0.1-3 mM) to produce blockade, but was more potent. As with L-arginine, L-NMMA (0.1-1 mM) reversed established submaximal blockade of NANC relaxation induced by L-NOARG (1 microM) or L-NAME (1 microM), but had little effect on maximal blockade induced by these agents. 7. These findings suggest a complex series of interactions between L-arginine and certain of its NG-substituted analogues that are commonly used to inhibit nitric oxide synthase. The most striking new finding is that L-NMMA does not block NANC relaxation in the BRP, but acts with greater potency than the endogenous substrate, L-arginine, to inhibit the blockade induced by L-NOARG or L-NAME.Even on rat anococcygeus where L-NMMA acts as a partial blocker of NANC relaxation, further blockade by L-NOARG is inhibited.

Animals↗